Biomedical Research Centre, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Address correspondence to: Colby Zaph, Biomedical Research Centre, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada. Phone: 604.822.7231; Fax: 604.822.7815; E-mail: email@example.com.
First published November 22, 2010 - More info
See the related article beginning on page 4332.
Nosocomial infections (i.e., infections acquired as a result of treatment in a hospital or health care unit) result in approximately 100,000 deaths and cost more than 25 billion dollars per year in the US alone. These infections are caused primarily by bacteria and affect mainly immunosuppressed patients. However, not all patients acquire infections, and the events leading up to infection are unclear. In this issue of the JCI, Ubeda et al. report how acquisition of one such infection, vancomycin-resistant Enterococcus faecium (VRE), is linked to a shift in the microbial flora following antibiotic treatment. This study highlights the potential for high-throughput sequencing of intestinal microbiota as a means to identify high-risk populations.
Nosocomial infections are infections acquired as a result of treatment in a hospital or health care unit. They are increasingly becoming a significant public health problem. It is thought that 5%–10% of patients entering hospitals worldwide develop a hospital-acquired infection (HAI) (1). The global growth of antibiotic-resistant bacterial strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VRE), has complicated the control of HAIs and highlights the need for a better understanding of how HAIs develop, are acquired, and may be controlled.
Intestinal Enterococcus infections are among the most common type of infection acquired by hospitalized patients. While enterococcal infections are much less capable of causing disease than HAIs such as Clostridium difficile and S. aureus, they still cause complications, prolong hospital stays, and can be fatal, particularly those caused by VRE. Fatal VRE infections, which occur upon bacterial invasion of the bloodstream, primarily affect immunocompromised patients such as those undergoing bone marrow or hematopoietic stem cell transplantation (HSCT) (2). It has been estimated that up to 50% of HSCT patients acquire VRE, and infection with VRE is independently associated with increased mortality in these patients (3). Identifying high-risk patients and developing novel methods to combat VRE are critical components in combating HAIs. The study by Ubeda et al. in this issue of the JCI begins to address this in both mice and humans using high-throughput sequencing analysis of commensal flora populations (4).
Over the past several years, interest in understanding the relationship between the commensal flora and disease states has increased markedly. It is clear that changes in the flora have a dramatic effect on the outcomes of many diseases and directly or indirectly affect immune homeostasis and function (5). For example, mice lacking all commensal bacteria (germ-free mice) have dramatically altered immune systems (6, 7) and immune responses at enteric and peripheral sites (8, 9). Furthermore, it has been shown in humans and animals that antibiotic-induced changes in the commensal flora are dramatic and long-lived (10) and have consequences for susceptibility to intestinal infections, including VRE (11).
While the exact role of the commensal flora in intestinal homeostasis is unclear, there are several studies that have identified components of this regulatory network (Figure 1). First, interactions between the host and the commensal flora via MyD88-dependent Toll-like receptor (TLR) activation are critical for maintenance of intestinal homeostasis (12, 13). Whether commensal bacteria are recognized by intestinal epithelial cells (IECs) or by intestinal antigen-presenting cells such as DCs and macrophages is not clear. However, mice with an IEC-specific deletion of the gene encoding IκB kinase-γ (IKK-γ; also known as NEMO) spontaneously develop intestinal inflammation (14), suggesting that NF-κB activation — possibly initiated by TLR activation by commensal bacteria — is playing a critical role in maintaining the host-commensal homeostatic relationship. The regulatory role of commensal bacteria may be to activate the intestinal immune response to control potentially pathogenic bacteria, as it has been shown that colonization of germ-free mice with a defined flora leads to the expression of several antimicrobial peptides, including the secreted C-type lectin regenerating islet–derived IIIγ (REGIIIγ), which is directly toxic to Gram-positive commensal and pathogenic bacteria (15, 16), and the goblet cell–specific protein resistin-like molecule-β (RELMβ) (17). In addition, antibiotic treatment of mice leads to a reduction in total numbers of bacteria, loss of REGIIIγ and RELMβ expression (11, 18), and increased susceptibility to outgrowth of, or infection with, intestinal bacterial pathogens such as Salmonella typhimurium (19–21) and VRE (11). Thus, the commensal flora are a critical component in maintaining the steady state as well as in preventing the outgrowth of potentially pathogenic species. However, the dynamics of the commensal flora prior to colonization by a pathogenic species is not known, and whether any predictions about disease progression can be made is unclear.
Antibiotic treatment leads to long-term changes in the commensal flora and susceptibility to VRE. (A) In the steady state, interactions between commensal bacteria and host cells in the intestine — primarily epithelial cells — result in the production of antimicrobial effector proteins (AMPs), such as REGIIIγ and RELMβ, that shape the commensal populations. The production of AMPs in this context may be dependent on NF-κB, which is presumed to be activated by TLR recognition of commensal bacterial products. In this state, mice are resistant to VRE infection. (B and C) Following transient antibiotic treatment, the numbers and diversity of the bacterial populations are severely reduced. Antibiotic treatment — presumably through a reduction in commensal bacteria — also results in decreased expression of AMPs. These changes result in long-lived increased susceptibility to VRE.
High-throughput pyrosequencing of bacterial 16S rDNA sequences allows for nonbiased, global analysis of the relative composition of bacterial populations in vivo. Using this technique, Ubeda et al. characterized the effects of several antibiotic regimens on the composition of the intestinal microbiome in mice (4); that is, they investigated how antibiotic treatment affected the relative frequencies of bacterial populations by quantifying the genomes of all the microorganisms that live in the intestine of a healthy adult mouse (the microbiome). Interestingly, a transient 7-day antibiotic treatment resulted in a dramatic shift in the commensal populations, with the outgrowth of several minor populations of bacteria, including Enterobacteriaceae, Clostridium, and Enterococcus species, bacteria that tend to be causative agents of nosocomial infections. Furthermore, several populations (primarily from the Bacteroidetes phylum) failed to recover after antibiotic withdrawal. These changes in the flora allowed normally resistant mice to become susceptible to VRE infection. Thus, the composition of the bacterial flora was critical in restraining the outgrowth of potentially pathogenic species, a pattern that has also been observed in animals with S. typhimurium infection (19–21).
Consistent with previous studies (10), these changes in bacterial populations observed by Ubeda and colleagues were long-lived and failed to return to normal, even after several months (4). One striking finding in the study of Ubeda et al. was that, even 2 months after antibiotic treatment, mice were still susceptible to VRE infection. These results suggest that transient antibiotic treatments result in long-term changes in the commensal bacterial populations that predispose the host to certain infections. Although the molecular mechanisms associated with this increased susceptibility remain unclear, the potential identification of a signature at the level of bacterial populations may provide a novel analytical tool to identify patients predisposed to fatal VRE infections.
To directly test whether a bacterial population signature could identify patients predisposed to fatal VRE infections, Ubeda et al. examined the microbiomes of human patients undergoing allogeneic HSCTs, a group at high risk for developing HAIs (4). All HSCT patients received prophylactic antibiotic treatment upon admission, during fever episodes, and at any point when neutrophil numbers decreased, so as to protect them against potential bacterial infections caused by neutropenia. Antibiotic use was not consistent, although most patients received ciprofloxacin, vancomycin, and trimethoprim-sulfamethoxazole at some point during the observation period. During the course of the study, two patients developed systemic VRE infections. The patients that developed VRE bacteremia displayed a striking change in the intestinal flora immediately prior to VRE infection, with a total shift toward bacteria from the genus Enterococcus as the dominant microbial population. Thus, the intestinal domination by Enterococcus species that preceded bloodstream invasion suggests that monitoring of fecal bacterial populations may provide a warning of impending systemic infections in immunocompromised patients and offer an opportunity for therapeutic intervention.
The shift in commensal flora to a single genus in immunocompromised patients is in striking contrast to data in healthy volunteers treated with ciprofloxacin, who lost bacterial diversity but did not acquire overgrowth by a single species (10). This highlights the important role of the host immune response in regulating commensal bacterial populations (Figure 2). The production of immune mediators in the gut — such as IgA (22); effector T cell– and DC-derived cytokines, including IL-17A, IL-22, and IL-23 (23, 24); and regulatory molecules, including TGFβ and retinoic acid (25) — may all contribute to maintaining a balanced commensal flora. Thus, the status of the immune system is also a critical component in commensal homeostasis, further highlighting the closely linked host-commensal relationship.
The role of the immune system in regulation of the commensal microflora. (A) In healthy subjects, recovery from antibiotic treatment results in minor changes to the diversity of the commensal flora. Immune mechanisms, including production of commensal-specific IgA, effector and regulatory cytokines, and retinoic acid that can act on IECs and other immune cells, may all contribute to the maintenance of intestinal homeostasis. (B) In contrast, immunocompromised patients that have impaired B cell, T cell, and DC responses often do not recover bacterial diversity following antibiotic treatment; in some cases, a single genus dominates the flora.
The study by Ubeda and colleagues (4) raises questions about the current use of antibiotics and how at-risk patients are identified. Antibiotic treatment of high-risk patients will not stop, but a closer examination of the effects of different classes of antibiotics on commensal populations and their subsequent consequences on infections should be investigated. While Ubeda et al. focused on VRE (4), other HAIs may not behave similarly, and thus global strategies may not apply. However, the use of high-throughput sequencing allows for a nonbiased global analysis of commensal populations, thereby potentially identifying distinct signatures in other HAIs. Furthermore, it is clear that the interactions between the commensal flora and the host immune system are bidirectional, with important ramifications for intestinal homeostasis. Future studies correlating intestinal and peripheral immune responses with commensal signatures may provide novel methods not only to affect the commensal flora, but also to regulate immune responses through manipulation of commensal populations.
The author is funded by Canadian Institutes of Health Research grants MSH-95368, MOP-89773, and MOP-106623 and by Canada Foundation for Innovation.
Conflict of interest: The author has declared that no conflict of interest exists.
Citation for this article:J Clin Invest. 2010;120(12):4182–4185. doi:10.1172/JCI45263.
See the related article beginning on page 4332.
Copyright © 2016 American Society for Clinical Investigation